

Special Issue

Thrombosis and Coagulopathy

Message from the Guest Editor

Cancer patients are at higher risk of developing thromboembolic events. Low-molecular-weight heparin remains the standard anticoagulant therapy in a cancer setting. However, direct oral anticoagulants have recently changed the therapeutic approach to the treatment of venous thromboembolism in cancer patients. This Special Issue will focus on the treatment of venous thromboembolism in patients affected by solid and hematologic malignancies.

Guest Editor

Dr. Antonio Chistolini

Hematology Department of Translational and Precision Medicine,
Sapienza University of Rome, Rome, Italy

Deadline for manuscript submissions

closed (31 December 2021)



Diseases

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/59846

Diseases
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diseases@mdpi.com

[mdpi.com/journal/
diseases](https://mdpi.com/journal/diseases)





Diseases

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
diseases](https://mdpi.com/journal/diseases)



About the Journal

Message from the Editor-in-Chief

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

Diseases is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Omar Cauli

Frailty and Cognitive Impairment—FROG Research Group, University of Valencia, 46010 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).